Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Jumps 62.8%

Posted by George Bondi on Sep 30th, 2026

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 226,620 shares, a growth of 62.8% from the August 31st total of 139,192 shares. Approximately 1.4% of the company’s shares are short sold. Based on an average daily trading volume, of 67,897 shares, the days-to-cover ratio is presently 3.3 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MRKR shares. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Friday, August 21st. Weiss Ratings upgraded shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Marker Therapeutics currently has an average rating of “Hold” and an average price target of $10.00.

Read Our Latest Stock Analysis on Marker Therapeutics

Marker Therapeutics Stock Down 2.3%

Marker Therapeutics stock traded down $0.03 during mid-day trading on Wednesday, hitting $1.07. 35,195 shares of the company’s stock were exchanged, compared to its average volume of 149,828. The firm has a market capitalization of $17.92 million, a P/E ratio of -2.62 and a beta of 1.53. Marker Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.46. The company’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.36.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 56.96% and a negative net margin of 343.03%. Research analysts expect that Marker Therapeutics will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently raised its stake in Marker Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) by 41.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 175,294 shares of the company’s stock after purchasing an additional 51,644 shares during the quarter. Renaissance Technologies LLC owned 1.05% of Marker Therapeutics worth $228,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc (NASDAQ: MRKR) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s approach uses multiTAA-specific T cells, which are designed to recognize and attack multiple tumor-associated antigens rather than a single target. Marker Therapeutics is developing these therapies for patients with solid tumors and certain hematologic malignancies.

The company’s lead investigational product, MT-601, is an autologous multiTAA-specific T-cell therapy being evaluated in clinical development, including for pancreatic cancer.